A meta-analysis of clinical benefit rates for fulvestrant 500 mg vs. alternative endocrine therapies for hormone receptor-positive advanced breast cancer

BACKGROUND: Fulvestrant, a selective estrogen receptor degrader, is approved for first- and second-line treatment of postmenopausal women with hormone receptor-positive advanced breast cancer (ABC). METHODS: Meta-analysis of randomized controlled trials (RCTs) evaluating fulvestrant 500 mg in postme...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Breast Cancer
Hlavní autoři: Robertson, John F. R., Jiang, Zefei, Di Leo, Angelo, Ohno, Shinji, Pritchard, Kathleen I., Ellis, Matthew, Bradbury, Ian, Campbell, Christine
Médium: Artigo
Jazyk:Inglês
Vydáno: Springer Japan 2019
Témata:
Original Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC6821663/
https://ncbi.nlm.nih.gov/pubmed/31079343
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s12282-019-00973-4
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky